Compass Therapeutics

Home
About
Platform
Pipeline
Clinical Trials
Join Us
Investors
Contact

Novel class of NK engagers targeting NKp30 selected from unbiased screen of common light chain based bispecific antibodies

Novel class of NK engagers targeting NKp30 selected from unbiased screen of common light chain based bispecific antibodies

Post navigation

Previous PostPrevious A versatile platform for efficient affinity optimization of common light chain multi-specific antibodies

Next PostNext A novel class of Innate Cell Engagers targeting NKp30

Search for:

Recent Comments

Archives

Categories

No categories

Meta

Log in
Entries feed
Comments feed
WordPress.org

© 2023 Compass Therapeutics, Inc.
Terms & Conditions
Privacy Policy

Home
About
Platform
Pipeline
Clinical Trials
Join Us
Investors
Contact